<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431312</url>
  </required_header>
  <id_info>
    <org_study_id>HBV-001</org_study_id>
    <nct_id>NCT02431312</nct_id>
  </id_info>
  <brief_title>Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects</brief_title>
  <official_title>Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability &amp; Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label study that evaluated the safety, tolerability, and immunogenicity of
      dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen [HBsAg] and
      Hepatitis B core antigen [HBcAg]) and INO-9112 (DNA plasmid encoding human interleukin 12)
      delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide analogue treated participants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2015</start_date>
  <completion_date type="Actual">May 22, 2018</completion_date>
  <primary_completion_date type="Actual">May 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Assessment (Composite of multiple measures: pain (VAS), adverse events, lab abnormalities, changes in vital signs)</measure>
    <time_frame>Signing of ICF through up to 76 weeks following the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:
Local pain immediately after Study Treatment/EP and at select times using a visual analog scale (VAS) from 0 to 10, with 0 representing &quot;No Pain&quot; and 10 representing &quot;Worst Pain&quot;
Frequency and severity of local and systemic events for at least 7 days after Study Treatment/EP
Frequency and severity of laboratory abnormalities
Frequency and severity of all adverse events
Changes in vital signs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Assessment</measure>
    <time_frame>Baseline (screening and first dose) and select points up to 76 weeks after the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including
Breadth and Magnitude of antigen specific cellular immune responses
Interferon-ɣ ELISpot
Flow Cytometry for T-cell activation, cytolytic phenotype, memory phenotype
Breadth and Magnitude of antigen specific ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral/Antiviral Assessment</measure>
    <time_frame>Screening and/or first dose and select points up to 76 weeks after the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:
Evaluate effect on HBsAg kinetics as measured in the quantitative HBsAg assay
Evaluate effect on maintenance of HBV DNA suppression (&lt; 90 IU/ml) as measured in the quantitative viral load assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Assessment</measure>
    <time_frame>Screening and/or first dose and select points up to 76 weeks after the first dose</time_frame>
    <description>Composite outcome measure consisting of multiple measures, including:
Relationship between immunogenicity and antiviral response
Expression of individual markers potentially predictive of immunogenic and antiviral responses</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A: low dose, standard regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 or 4 doses of 0.3 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: mid dose, standard regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 or 4 doses of 2 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A: high dose, standard regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 or 4 doses of 9 mg INO-1800 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: mid dose, standard regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 or 4 doses of 2 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: high dose, standard regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 or 4 doses of 9 mg INO-1800 + 0.25 mg INO-9112 delivered by EP in a standard regimen while continuing treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control: nucleos(t)ide analogue treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants continued treatment with nucleos(t)ide analogue treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-1800</intervention_name>
    <description>INO-1800 delivered by EP</description>
    <arm_group_label>Group A: high dose, standard regimen</arm_group_label>
    <arm_group_label>Group A: low dose, standard regimen</arm_group_label>
    <arm_group_label>Group A: mid dose, standard regimen</arm_group_label>
    <arm_group_label>Group B: high dose, standard regimen</arm_group_label>
    <arm_group_label>Group B: mid dose, standard regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>INO-9112</intervention_name>
    <description>INO-9112 delivered by EP</description>
    <arm_group_label>Group B: high dose, standard regimen</arm_group_label>
    <arm_group_label>Group B: mid dose, standard regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleos(t)ide Analogue Treatment</intervention_name>
    <description>Continued treatment with nucleos(t)ide analogue</description>
    <arm_group_label>Active Control: nucleos(t)ide analogue treatment</arm_group_label>
    <arm_group_label>Group A: high dose, standard regimen</arm_group_label>
    <arm_group_label>Group A: low dose, standard regimen</arm_group_label>
    <arm_group_label>Group A: mid dose, standard regimen</arm_group_label>
    <arm_group_label>Group B: high dose, standard regimen</arm_group_label>
    <arm_group_label>Group B: mid dose, standard regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Chronic Hepatitis B virus infection

          -  Negative for Hepatitis A IgM, C, D and HIV

          -  Liver biopsy, Fibroscan® or equivalent elastography-based test obtained within the
             past 6 months demonstrating liver disease without evidence of bridging fibrosis or
             cirrhosis supported by platelet count greater than the central laboratory LLN at
             screening

          -  Positive for Hepatitis B surface antigen (≥250 IU/mL at screening)

          -  Nucleos(t)ide treatment for at least 1 year with ongoing nucleos(t)ide analogue
             treatment at randomization

          -  HBV DNA &lt;90 IU/mL for ≥6 months prior to randomization

          -  Screening laboratory values within normal range

          -  ALT ≤1.5x upper limit of normal (ULN) from 2 measurements separated by at least 14
             days during the 6 months prior to randomization and ALT at screening ≤1.5x ULN

          -  AST, TBili, DBili, GGT, Alk Phos and albumin within normal range or judged to be not
             clinically significant by PI and medical monitor at screening

          -  For men and women who are not postmenopausal [i.e. ≥ 12 months of non-therapy-induced
             amenorrhea, confirmed by follicle stimulating hormone (FSH), if not on hormone
             replacement] or surgically sterile (vasectomy in males or absence of ovaries and/or
             uterus in females) agreement to remain abstinent or use 1 highly effective or combined
             contraceptive methods that result in a failure rate of &lt; 1% per year during the
             treatment period and at least through week 12 after last dose

        EXCLUSION CRITERIA:

          -  Pregnant or breastfeeding females

          -  Positive serum pregnancy test at screening or positive urine pregnancy test at
             randomization

          -  Use of topical corticosteroids at or near the intended administration site

          -  Autoimmune disorders, transplant recipients, other immunosuppression including any
             concurrent condition requiring the use of immunosuppressive/immunomodulating agents
             (eye drop-containing and infrequent inhaled corticosteroids are permissible)

          -  Need for systemic antiviral treatment (other than for chronic hepatitis B infection)

          -  Documented history or other evidence of decompensated liver disease (e.g., ascites,
             bleeding from esophageal varices, Child-Pugh clinical classification B or C)

          -  History of liver cirrhosis demonstrated by biopsy, Fibroscan® or equivalent
             elastography-based test

          -  History of other evidence of a medical condition associated with chronic liver disease
             [e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, non-alcoholic
             steatohepatitis (NASH), toxin exposure, thalassemia, etc.]

          -  Documented history or other evidence of metabolic liver disease within 1yr of
             randomization

          -  Abnormal renal function including serum creatinine &gt;ULN or calculated creatinine
             clearance &lt;70 mL/min (using the Cockcroft Gault formula)

          -  History of or suspicion of HCC

          -  Screening alpha fetoprotein ≥13 ng/mL

          -  Prior history or current malignancy other than adequately treated BCC, unless history
             of BCC is near intended administration site

          -  History of significant medical conditions [e.g., cardiac (including ventricular or
             supraventricular arrhythmias), renal disease, pulmonary, gastrointestinal,
             neurological]

          -  Significant acute infection (e.g., influenza, local infection) or any other clinically
             significant illness within 2 weeks of randomization

          -  Administration of any blood product within 3 mon of randomization

          -  History of seizures (unless seizure free for 5yrs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ShuPing Yang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research and Education, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Schiff Center for Liver Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai - PRIME</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Physicians Company, LLC/Division of Digestive Diseases</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbourview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <zip>1023</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou</city>
        <state>Taoyuan County</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharaj Nakorn Chiang Mai Hospital</name>
      <address>
        <city>Tha Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Srinagarind Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <state>Muang District</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>October 11, 2019</last_update_submitted>
  <last_update_submitted_qc>October 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic HBV</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>DNA vaccine</keyword>
  <keyword>electroporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

